갈라닌 수용체는 말초신경계와 중추신경계, 내분비계 전반에서 발견된다.지금까지 세 가지 아형이 존재하는 것으로 알려져 있는데, GAL-R1, GAL-R2, GAL-R3이다.[2]2009년 현재 수용체 아형별 녹아웃 생쥐의 생성과 [3][4]갈란인 수용체 아형에 대한 최초의 선택적 리간드(ligands)와 관련하여 현재 큰 진전이 이루어지고 있지만, 각 아형의 구체적인 기능은 완전하게 해명되어야 한다.선택적 갈라닌 작용제는 항경련제인 반면,[5][6][7] 길항제들은 동물들에게 항우울제와 항불안제 효과를 생산하기 때문에 [8][9][10][11][12]갈라닌 수용체를 위한 작용제나 길항제 리간드는 인간에게 잠재적으로 치료적 화합물이 될 수 있다.null
^Lang R, Gundlach AL, Kofler B (2007). "The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease". Pharmacol. Ther. 115 (2): 177–207. doi:10.1016/j.pharmthera.2007.05.009. PMID17604107.
^Barr AM, Kinney JW, Hill MN, Lu X, Biros S, Rebek J, Bartfai T (September 2006). "A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests". Neuroscience Letters. 405 (1–2): 111–5. doi:10.1016/j.neulet.2006.06.033. PMID16854525. S2CID39707220.
^Lu X, Sharkey L, Bartfai T (June 2007). "The brain galanin receptors: targets for novel antidepressant drugs". CNS & Neurological Disorders Drug Targets. 6 (3): 183–92. doi:10.2174/187152707780619335. PMID17511615.
^Kuteeva E, Hökfelt T, Wardi T, Ogren SO (June 2008). "Galanin, galanin receptor subtypes and depression-like behaviour". Cellular and Molecular Life Sciences. 65 (12): 1854–63. doi:10.1007/s00018-008-8160-9. PMID18500640. S2CID27882520.
^Kuteeva E, Wardi T, Lundström L, Sollenberg U, Langel U, Hökfelt T, Ogren SO (October 2008). "Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level". Neuropsychopharmacology. 33 (11): 2573–85. doi:10.1038/sj.npp.1301660. PMID18172432. S2CID10273560.
^Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE (October 2007). "Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon". Neuropeptides. 41 (5): 307–20. doi:10.1016/j.npep.2007.05.001. PMID17637475. S2CID25988178.
^Bulaj G, Green BR, Lee HK, Robertson CR, White K, Zhang L, Sochanska M, Flynn SP, Scholl EA, Pruess TH, Smith MD, White HS (December 2008). "Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities". Journal of Medicinal Chemistry. 51 (24): 8038–47. doi:10.1021/jm801088x. PMID19053761.
^ abSollenberg UE, Runesson J, Sillard R, Langel U (March 2010). "Binding of Chimeric Peptides M617 and M871 to Galanin Receptor Type 3 Reveals Characteristics of Galanin Receptor–Ligand Interaction". International Journal of Peptide Research and Therapeutics. 16 (1): 17–22. doi:10.1007/s10989-009-9197-9. S2CID36850989.
^Saar I, Runesson J, McNamara I, Järv J, Robinson JK, Langel U (2011). "Novel galanin receptor subtype specific ligands in feeding regulation". Neurochemistry International. 58 (6): 714–720. doi:10.1016/j.neuint.2011.02.012. PMID21333705. S2CID23682808.
^Khan, SA, Zia, K, Ashraf, S, khan, A, Ul-Haq, Z (October 2021). "Theoretical investigation of selective ligand binding mode of galanin receptors". Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2021.1977703. PMID34632940.
외부 링크
"Galanin Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.